Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Elise C Kohn

Showing results (11-20 of 180) with videos related to

Pageof 18
Sort By:
Cancer|September 15, 2020
Intraperitoneal chemotherapy: Hot, timely, and relevant?Helen J Mackay, Elise C Kohn
Gynecologic Oncology|December 8, 2017
Clinical trials in gynecologic oncology: Past, present, and futureChristina M Annunziata, Elise C Kohn
Cancer|July 16, 2008
Rationale for combination use of targeted agents in ovarian cancer: do we have one?Robert L Coleman, Elise C Kohn
Journal of the National Cancer Institute|August 8, 2002
Stromal therapy: the next step in ovarian cancer treatmentLance A Liotta, Elise C Kohn
Gynecologic Oncology|June 25, 2003
Is there a genomic basis for primary chemoresistance in ovarian cancer?Christina M Annunziata, Elise C Kohn
Journal of the National Cancer Institute|September 25, 2013
Novel facts about FAK: new connections to drug resistance?Christina M Annunziata, Elise C Kohn
Frontiers in Oncology|February 24, 2018
Editorial: New Approaches to Radiation-Therapeutic Agent Cancer Care for WomenCharles A Kunos, Elise C Kohn
Cancer|May 13, 2017
Drug development and registration: Challenges and opportunities in ovarian cancerS Percy Ivy, Elise C Kohn
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|June 1, 2017
Whence High-Grade Serous Ovarian CancerElise C Kohn, S Percy Ivy
Clinical Colorectal Cancer|April 6, 2005
Proteomic approaches in colon cancer: promising tools for new cancer markers and drug target discoveryRiccardo Alessandro, Claudio Belluco, Elise C Kohn
Pageof 18

Showing results (11-20 of 180) with videos related to

Sort By:
Pageof 18
Cancer|September 15, 2020
Intraperitoneal chemotherapy: Hot, timely, and relevant?Helen J Mackay, Elise C Kohn
Gynecologic Oncology|December 8, 2017
Clinical trials in gynecologic oncology: Past, present, and futureChristina M Annunziata, Elise C Kohn
Cancer|July 16, 2008
Rationale for combination use of targeted agents in ovarian cancer: do we have one?Robert L Coleman, Elise C Kohn
Journal of the National Cancer Institute|August 8, 2002
Stromal therapy: the next step in ovarian cancer treatmentLance A Liotta, Elise C Kohn
Gynecologic Oncology|June 25, 2003
Is there a genomic basis for primary chemoresistance in ovarian cancer?Christina M Annunziata, Elise C Kohn
Journal of the National Cancer Institute|September 25, 2013
Novel facts about FAK: new connections to drug resistance?Christina M Annunziata, Elise C Kohn
Frontiers in Oncology|February 24, 2018
Editorial: New Approaches to Radiation-Therapeutic Agent Cancer Care for WomenCharles A Kunos, Elise C Kohn
Cancer|May 13, 2017
Drug development and registration: Challenges and opportunities in ovarian cancerS Percy Ivy, Elise C Kohn
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|June 1, 2017
Whence High-Grade Serous Ovarian CancerElise C Kohn, S Percy Ivy
Clinical Colorectal Cancer|April 6, 2005
Proteomic approaches in colon cancer: promising tools for new cancer markers and drug target discoveryRiccardo Alessandro, Claudio Belluco, Elise C Kohn
Pageof 18